Table 4.

Summary of head-to-head trial data for GLP-1 receptor agonists.

Drug	Within class comparability of A1C lowering efficacy	Within class comparability of effect on weight	Within class comparability of GI adverse effects
Exenatide (twice daily)	Low	Low	Highest
Lixisenatide	Low	Low	Intermediate
Liraglutide	High	High	Intermediate
Exenatide XR	Intermediate	Low	Low
Dulaglutide	High	Intermediate	Intermediate/high
Semaglutide	Highest	Highest	High
Semaglutide (oral)	High/highest	Highest	Intermediate/high

A1C, hemoglobin A1C; GI, gastrointestinal; GLP-1 RA, glucagon-like peptide-1 receptor agonists.